4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

The emergence and global dissemination of antimicrobial resistance among pathogenic bacteria represent one of the most critical challenges in clinical medicine. In the clinical microbiology laboratory, standardized antimicrobial susceptibility testing (AST) guides targeted patient therapy and tracks multi-drug-resistant (MDR) phenotypes. The Clinical and Laboratory Standards Institute (CLSI) establishes standardized parameters that govern media formulation, inoculum standardization, incubation conditions, and interpretive breakpoints. Mastery of AST methodologies, technical troubleshooting, and resistance mechanisms is heavily weighted on the MTLE.

---

1. Antimicrobial Susceptibility Testing Methodologies

                          ┌──────────────────────────────────────────────┐
                          │     Antimicrobial Susceptibility Methods     │
                          └──────────────────────┬───────────────────────┘
                                                 │
         ┌───────────────────────────────────────┼──────────────────────────────────────┐
         ▼                                       ▼                                      ▼
  ┌──────────────┐                       ┌──────────────┐                       ┌──────────────┐
  │ Kirby-Bauer  │                       │Broth Dilution│                       │E-Test / Grad.│
  │Disk Diffusion│                       │  (MIC & MBC) │                       │  Diffusion   │
  └──────┬───────┘                       └──────┬───────┘                       └──────┬───────┘
         │                                      │                                      │
  • Mueller-Hinton Agar                  • 2-fold serial dilutions              • Plastic reagent strip with
  • Agar depth: EXACTLY 4 mm               in microtiter broth                    predefined exponential drug
  • pH: 7.2 to 7.4                       • MIC: Lowest concentration              concentration gradient
  • 0.5 McFarland inoculum                 visibly inhibiting growth            • Direct quantitative MIC
    (1.5 x 10^8 CFU/mL)                  • MBC: Lowest concentration              read where ellipse
  • Incubation: 35°C in                    killing ≥99.9% inoculum                intersects strip scale
    ambient air for 16-18 hr             • Tolerance: MBC/MIC ≥ 32

Kirby-Bauer Agar Disk Diffusion Method

Standardized according to CLSI document M02:

• Standard Plating Medium: Mueller-Hinton Agar (MHA). MHA demonstrates excellent batch-to-batch reproducibility, low concentrations of sulfonamide inhibitors (thymidine and thymine), supports the growth of non-fastidious aerobes, and features controlled divalent cation concentrations ($Ca^{2+}, Mg^{2+}$). Fastidious organisms require supplementation: Streptococcus pneumoniae and other streptococci are tested on MHA supplemented with $5\%$ defibrinated sheep blood (MHA-F).
• Standard Agar Depth: The depth of MHA in Petri dishes must be precisely $4\text{ mm}$ (acceptable range: $3.5\text{ to }4.5\text{ mm}$; approximately $25\text{ to }30\text{ mL}$ for a $100\text{ mm}$ plate, $60\text{ to }70\text{ mL}$ for a $150\text{ mm}$ plate).
• Medium pH: The pH must be within $7.2\text{ to }7.4$ measured at room temperature ($25^\circ\text{C}$).
• Inoculum Standardization ($0.5\text{ McFarland}$): Bacterial colonies from an $18\text{--}24\text{ hour}$ agar plate are suspended in sterile saline or broth to match the turbidity of a $0.5\text{ McFarland standard}$. Chemically, this standard is prepared by mixing $0.5\text{ mL}$ of $0.048\text{ M }BaCl_2$ ($1.175\%\text{ w/v }BaCl_2 \cdot 2H_2O$) with $99.5\text{ mL}$ of $0.18\text{ M }H_2SO_4$ ($1\%\text{ v/v}$), producing a fine barium sulfate ($BaSO_4$) precipitate. Its spectrophotometric absorbance at $625\text{ nm}$ is $0.08\text{ to }0.13$, corresponding to an approximate bacterial suspension density of $1.5 \times 10^8\text{ CFU/mL}$.
• Inoculation Procedure & the 15-Minute Rule: A sterile cotton swab is dipped into the standardized suspension, rotated firmly against the inner tube wall above the liquid level to expel excess moisture, and swabbed over the entire MHA surface in three planes ($60^\circ$ rotations), finishing with a rim sweep. Plates must be inoculated within 15 minutes of suspension preparation; antimicrobial disks must be applied within 15 minutes of inoculation; and plates must be placed into the incubator within 15 minutes of disk deposition.
• Disk Spacing: Disks must be spaced $\ge 24\text{ mm}$ apart center-to-center; a maximum of 12 disks may be placed on a $150\text{ mm}$ plate, or 5 disks on a $100\text{ mm}$ plate.
• Incubation Parameters: Plates are inverted and incubated at $35\pm 2^\circ\text{C}$ in ambient air for 16 to 18 hours (24 hours for vancomycin and oxacillin against staphylococci and enterococci). Incubation in $CO_2$ is strictly prohibited for routine testing because dissolved $CO_2$ generates carbonic acid, lowering surface pH and altering antimicrobial activity.
• Measurement and Interpretation: Zones of complete inhibition are measured to the nearest whole millimeter ($mm$) across the underside of the plate against a non-reflecting black background. Results are categorized as Susceptible (S), Intermediate (I), or Resistant (R) based on CLSI M100 breakpoint tables.

Dilution Susceptibility Testing (MIC and MBC)

• Broth Microdilution: Performed in 96-well plastic microtiter trays containing two-fold serial dilutions of antimicrobials (e.g., $0.25, 0.5, 1, 2, 4, 8, 16, 32, 64\ \mu\text{g/mL}$) in cation-adjusted Mueller-Hinton broth (CAMHB). Inoculated to achieve a final bacterial concentration of $5 \times 10^5\text{ CFU/mL}$.
• Minimum Inhibitory Concentration (MIC): The lowest concentration of an antimicrobial agent (in $\mu\text{g/mL}$) that completely prevents visible in vitro bacterial growth after $16\text{ to }20\text{ hours}$ of incubation.
• Minimum Bactericidal Concentration (MBC): Determined by subculturing a fixed volume (e.g., $10\ \mu\text{L}$) from all clear microtiter wells showing no visible turbidity onto antibiotic-free agar plates. The MBC is the lowest antimicrobial concentration that kills $\ge 99.9\%$ ($3\log_{10}$ reduction) of the original bacterial inoculum.
• Antimicrobial Tolerance: An organism is defined as tolerant when the $\text{MBC} / \text{MIC} \ge 32$. A tolerant pathogen is inhibited by standard concentrations but requires lethal doses far exceeding achievable clinical levels (e.g., Enterococcus faecalis or S. aureus in infective endocarditis treated with cell-wall active monotherapy).

Gradient Diffusion Method (E-Test)

Utilizes a plastic reagent strip impregnated with a continuous, predefined exponential gradient of dried antimicrobial agent spanning 15 two-fold dilutions. When placed onto an inoculated agar lawn, the antimicrobial diffuses immediately, generating a symmetrical, teardrop-shaped elliptical zone of inhibition. The quantitative MIC is read directly where the edge of the inhibition ellipse intersects the calibrated numerical scale printed on the strip face.

---

2. Technical Troubleshooting and Quality Control Errors in Kirby-Bauer

Adherence to CLSI standardization eliminates systematic testing errors:

---

3. Major Bacterial Resistance Mechanisms and Specialized Phenotypic Detection

                    ┌────────────────────────────────────────────────────────┐
                    │         Major Bacterial Resistance Mechanisms          │
                    └───────────────────────────┬────────────────────────────┘
                                                │
         ┌───────────────────┬──────────────────┴──────────────────┬───────────────────┐
         ▼                   ▼                                     ▼                   ▼
  ┌──────────────┐    ┌──────────────┐                      ┌──────────────┐    ┌──────────────┐
  │     ESBL     │    │     CRE      │                      │     MRSA     │    │  iMLSB / erm │
  └──────┬───────┘    └──────┬───────┘                      └──────┬───────┘    └──────┬───────┘
         │                   │                                     │                   │
  • TEM, SHV, CTX-M   • KPC, NDM, VIM                       • mecA gene encodes • Erythromycin
  • Hydrolyzes 3rd/4th  • Hydrolyzes                          PBP2a (low beta-    induces 23S rRNA
    gen cephalosporins  carbapenems                           lactam affinity)    methylase
  • Clavulanate       • mCIM positive                       • 30 µg Cefoxitin   • D-Test: Blunting of
    synergy ≥5 mm       (E. coli growth)                      screen: ≤21 mm      clindamycin zone
    confirms ESBL     • eCIM: MBL zinc                        confirms MRSA       mandates reporting
                        chelation                                                 Clindamycin RESIST.

Extended-Spectrum $\beta$-Lactamases (ESBL)

• Molecular Mechanisms: Plasmid-encoded Class A serine $\beta$-lactamases (CTX-M, TEM, and SHV variants) found in Enterobacterales, most frequently Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, and Proteus mirabilis.
• Resistance Spectrum: Hydrolyze all penicillins, all cephalosporin generations (including 3rd- and 4th-generation: ceftriaxone, cefotaxime, ceftazidime, cefepime), and monobactams (aztreonam). They do NOT hydrolyze cephamycins (cefoxitin, cefotetan) or carbapenems, and are inhibited in vitro by $\beta$-lactamase inhibitors (clavulanic acid, sulbactam, tazobactam).
• Phenotypic Confirmatory Test (CLSI Combined Disk Method): Ceftazidime ($30\ \mu\text{g}$) and cefotaxime ($30\ \mu\text{g}$) disks are tested alone and in combination with clavulanic acid ($10\ \mu\text{g}$) on MHA. An increase of $\mathbf{\ge 5\text{ mm}}$ in zone of inhibition diameter for either antimicrobial agent tested in combination with clavulanate compared to the zone of the agent alone confirms an ESBL producer.

Carbapenem-Resistant Enterobacterales (CRE)

• Molecular Mechanisms: Production of carbapenemase enzymes capable of hydrolyzing carbapenems (ertapenem, meropenem, imipenem) as well as almost all $\beta$-lactams. Classified by Ambler scheme:
  • Class A: Klebsiella pneumoniae carbapenemase (KPC); serine carbapenemase inhibited by avibactam and vaborbactam.
  • Class B Metallo-$\beta$-Lactamases (MBL): NDM (New Delhi metallo-$\beta$-lactamase), VIM, IMP; require zinc ($Zn^{2+}$) at active site, inhibited by metal chelators (EDTA), refractory to avibactam.
  • Class D: OXA-48-like carbapenemases; weak carbapenemases that do not hydrolyze 3rd-gen cephalosporins unless paired with an ESBL.
• Phenotypic Detection (mCIM and eCIM):
  • Modified Carbapenem Inactivation Method (mCIM): A $10\ \mu\text{g}$ meropenem disk is incubated in a suspension of the test organism for 4 hours, then placed onto a lawn of susceptible E. coli ATCC 25922. If the test isolate produces carbapenemase, meropenem is hydrolyzed; E. coli grows up to the disk (zone $6\text{--}15\text{ mm}$, positive mCIM).
  • EDTA-modified CIM (eCIM): Testing the isolate simultaneously in broth containing EDTA. If EDTA chelates zinc and restores meropenem activity (zone increase $\ge 5\text{ mm}$ compared to mCIM), a metallo-$\beta$-lactamase is confirmed.

Methicillin-Resistant Staphylococcus aureus (MRSA)

• Molecular Mechanism: Mediated by acquisition of the $mecA$ gene (or $mecC$) integrated on the mobile Staphylococcal Cassette Chromosome mec (SCCmec). The $mecA$ gene encodes an altered transpeptidase called Penicillin-Binding Protein 2a (PBP2a) ($78\text{ kDa}$), which possesses an exceptionally low binding affinity for virtually all $\beta$-lactam antibiotics. Strains are clinically resistant to all penicillins, cephalosporins (except 5th-generation anti-MRSA cephalosporins like ceftaroline), carbapenems, and $\beta$-lactamase inhibitor combinations.
• Phenotypic Cefoxitin Disk Screen: The CLSI recommends a $30\ \mu\text{g}\text{ Cefoxitin disk}$ on MHA at $35^\circ\text{C}$ (read after 18 hours). Cefoxitin is a potent inducer of $mecA$-mediated PBP2a expression and produces sharper zone endpoints than oxacillin. A zone diameter of $\le 21\text{ mm}$ indicates $mecA$-positive MRSA ($\ge 22\text{ mm}$ is methicillin-susceptible S. aureus, MSSA).
• Oxacillin Salt Agar Screen: MHA containing $6\ \mu\text{g/mL}$ oxacillin and $4\%\text{ NaCl}$; inoculated and incubated at $35^\circ\text{C}$ for 24 hours. Any growth ($\ge 1$ colony) confirms oxacillin/methicillin resistance.
• Gold Standard Confirmation: Molecular PCR detection of the $mecA$ gene or latex agglutination assays detecting PBP2a protein.

Vancomycin-Resistant Enterococci (VRE)

• Molecular Mechanism: Acquired plasmid-mediated operons ($vanA$, $vanB$) reprogram cell wall peptidoglycan biosynthesis. The terminal pentapeptide target D-Alanyl-D-Alanine (D-Ala-D-Ala) is substituted with D-Alanyl-D-Lactate (D-Ala-D-Lac), reducing vancomycin binding affinity by 1,000-fold.
  • $vanA$: High-level inducible resistance to both vancomycin (MIC $\ge 64\ \mu\text{g/mL}$) and teicoplanin (MIC $\ge 16\ \mu\text{g/mL}$); primarily in Enterococcus faecium.
  • $vanB$: Variable resistance to vancomycin (MIC $4\text{ to }\ge 1024\ \mu\text{g/mL}$), but remains susceptible to teicoplanin.
  • $vanC$ (Intrinsic Resistance): Chromosomally encoded in Enterococcus gallinarum (motile) and Enterococcus casseliflavus (motile, yellow pigment). Synthesizes terminal D-Alanyl-D-Serine (D-Ala-D-Ser), conferring low-level, non-transferable vancomycin resistance (MIC $4\text{--}16\ \mu\text{g/mL}$; teicoplanin susceptible).
• Screening: Brain Heart Infusion (BHI) agar screen with $6\ \mu\text{g/mL}$ vancomycin; growth of $>1$ colony after 24 hours at $35^\circ\text{C}$ indicates resistance.

Inducible Macrolide-Lincosamide-Streptogramin B ($iMLS_B$) Resistance and the D-Test

• Mechanisms in Staphylococci and Streptococci:
  1. Efflux Pump ($msrA$ gene): Active macrolide-specific efflux pump. Confers resistance to 14- and 15-membered macrolides (erythromycin) only; lincosamides (clindamycin) remain fully active ($E\text{-R}, C\text{-S}$). Clindamycin therapy is clinically safe.
  2. Ribosomal Methylation ($erm$ gene): Erythromycin ribosome methylase dimethylates adenine residue A2058 in 23S rRNA, blocking binding of macrolides, lincosamides, and streptogramin B.
• The D-Test Principle: The $erm$ gene can be expressed constitutively ($cMLS_B$, resistant to both drugs) or inducibly ($iMLS_B$). In $iMLS_B$, erythromycin is a strong inducer of methylase translation, whereas clindamycin is an extremely weak inducer. In standard isolated testing, an $iMLS_B$ strain tests Erythromycin-Resistant and Clindamycin-Susceptible.
• Testing Procedure: An erythromycin disk ($15\ \mu\text{g}$) and clindamycin disk ($2\ \mu\text{g}$) are placed $15\text{ to }26\text{ mm}$ apart center-to-center on an MHA plate inoculated with the test isolate.
• Interpretation and Clinical Reporting: Erythromycin diffuses toward the clindamycin disk, inducing methylase synthesis in adjacent bacteria. This produces a flattened or blunted zone of inhibition around clindamycin adjacent to the erythromycin disk, creating a distinct letter "D" shape.
• Clinical Rule: An isolate with a positive D-test MUST be reported as Clindamycin-Resistant ($R$), because administration of clindamycin in vivo selects for high-frequency constitutive mutants, leading to clinical treatment failure.